Compare Moderna, Inc. (MRNA) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Sprott Uranium Miners ETF — how do they compare? Moderna, Inc. trades at $218.41 (market cap $78.65B), while Sprott Uranium Miners ETF trades at $46.2 (market cap $1.87B). The key difference: Moderna, Inc. is far larger — about 42.1× Sprott Uranium Miners ETF's market cap, and Moderna, Inc. is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Sprott Uranium Miners ETF for 60 Days on average.
| MRNA | URNM | |
|---|---|---|
Market Cap | $78.65B | $1.87B |
Volume | 37,373,437 | 1,586,926 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $203.46 | $83.99 |
52-Week Low | $22.36 | $46.09 |
Typical Hold Time | 59 Days | 60 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
URNM (Sprott Uranium Miners ETF) trades at $47.87, down 4.83% today amid bearish technical signals. The ETF faces selling pressure with 13 bearish moving average indicators, though oscillators remain neutral. Recent news highlights uranium's long-term growth potential driven by AI energy demand and government nuclear investments, with spot uranium prices rising 21.25% over the past year according to Sprott Asset Management (September 2026).
The uranium sector shows strong fundamental tailwinds from nuclear energy expansion and AI power needs, but URNM's technical weakness suggests near-term volatility. Investment opportunity exists in uranium supply deficits and contracting growth, while risks include ETF concentration and commodity price sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
